Alexander J Millman1, Sue Reynolds2, Jonathan Duffy3, Jufu Chen4, Paul Gargiullo5, Alicia M Fry6. 1. Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA; Epidemic Intelligence Service assigned to Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA. Electronic address: amillman@cdc.gov. 2. Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA. Electronic address: SNB9@cdc.gov. 3. Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road MS D-26, Atlanta, GA 30329, USA. Electronic address: LZD5@cdc.gov. 4. Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA. Electronic address: NCZ5@cdc.gov. 5. Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA. Electronic address: bpot6v6g@att.net. 6. Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road MS A-32, Atlanta, GA 30329, USA. Electronic address: AGF1@cdc.gov.
Abstract
BACKGROUND: Live attenuated influenza vaccine (LAIV) is safe in healthy children ⩾2years. The original clinical trials excluded individuals with underlying conditions; however, post-marketing data suggest LAIV may be safe for these populations. METHODS: We analyzed MarketScan Commercial Claims Databases from 2010 to 2012 to describe hospitalizations within 14days of vaccination among LAIV recipients. We evaluated LAIV recipients aged 2-18years and defined underlying conditions by presence of inpatient or outpatient ICD-9 code during the previous calendar year. We excluded asthma and immunocompromising conditions. We defined risk windows as 1-7days and 8-14days after vaccination; the control period was 12-4days prior to and 15-23days after vaccination. We conducted a self-controlled case series analysis using a conditional Poisson regression model to estimate incidence-rate ratios (IRR). RESULTS: 1,216,123 children aged 2-18years received LAIV from 2010 to 2012. 634 children met our inclusion criteria and were hospitalized during the observation period (12days prior to vaccination to 23days after vaccination). Of those hospitalized, 72 (11.4%) had non-asthma, non-immunocompromising underlying conditions. Children with non-asthma, non-immunocompromising underlying conditions had an all-cause hospitalization IRR of 1.1 (95% CI 0.6-2.0, p=0.83) in the 1-7day risk period and 0.9 (95% CI 0.4-1.7, p=0.67) in the 8-14day risk period. Children with no underlying conditions had an all-cause hospitalization IRR of 0.9 (0.8-1.2, p=0.60) in the 1-7day risk period and 1.1 (95% CI 0.9-1.3, p=0.53) in the 8-14day risk period. There were no differences in all-cause hospitalization risk in individuals with non-asthma, non-immunocompromising underlying conditions compared to those without underlying conditions in the 1-7day (p=0.88) or 8-14day (p=0.24) risk period. CONCLUSIONS: We found no evidence of differences in post-LAIV hospitalization risk among children with non-asthma, non-immunocompromising underlying conditions compared to healthy children.
BACKGROUND: Live attenuated influenza vaccine (LAIV) is safe in healthy children ⩾2years. The original clinical trials excluded individuals with underlying conditions; however, post-marketing data suggest LAIV may be safe for these populations. METHODS: We analyzed MarketScan Commercial Claims Databases from 2010 to 2012 to describe hospitalizations within 14days of vaccination among LAIV recipients. We evaluated LAIV recipients aged 2-18years and defined underlying conditions by presence of inpatient or outpatient ICD-9 code during the previous calendar year. We excluded asthma and immunocompromising conditions. We defined risk windows as 1-7days and 8-14days after vaccination; the control period was 12-4days prior to and 15-23days after vaccination. We conducted a self-controlled case series analysis using a conditional Poisson regression model to estimate incidence-rate ratios (IRR). RESULTS: 1,216,123 children aged 2-18years received LAIV from 2010 to 2012. 634 children met our inclusion criteria and were hospitalized during the observation period (12days prior to vaccination to 23days after vaccination). Of those hospitalized, 72 (11.4%) had non-asthma, non-immunocompromising underlying conditions. Children with non-asthma, non-immunocompromising underlying conditions had an all-cause hospitalization IRR of 1.1 (95% CI 0.6-2.0, p=0.83) in the 1-7day risk period and 0.9 (95% CI 0.4-1.7, p=0.67) in the 8-14day risk period. Children with no underlying conditions had an all-cause hospitalization IRR of 0.9 (0.8-1.2, p=0.60) in the 1-7day risk period and 1.1 (95% CI 0.9-1.3, p=0.53) in the 8-14day risk period. There were no differences in all-cause hospitalization risk in individuals with non-asthma, non-immunocompromising underlying conditions compared to those without underlying conditions in the 1-7day (p=0.88) or 8-14day (p=0.24) risk period. CONCLUSIONS: We found no evidence of differences in post-LAIV hospitalization risk among children with non-asthma, non-immunocompromising underlying conditions compared to healthy children.
Authors: G Falkenhorst; T Harder; C Remschmidt; M Terhardt; F Zepp; T Ledig; S Wicker; B Keller-Stanislawski; T Mertens Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2013-11 Impact factor: 1.513
Authors: Hector S Izurieta; Penina Haber; Robert P Wise; John Iskander; Douglas Pratt; ChrisAnna Mink; Soju Chang; M Miles Braun; Robert Ball Journal: JAMA Date: 2005-12-07 Impact factor: 56.272
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Randy Bergen; Steve Black; Henry Shinefield; Edwin Lewis; Paula Ray; John Hansen; Robert Walker; Colin Hessel; Julie Cordova; Paul M Mendelman Journal: Pediatr Infect Dis J Date: 2004-02 Impact factor: 2.129
Authors: Alison Tse Kawai; Lingling Li; Martin Kulldorff; Claudia Vellozzi; Eric Weintraub; Roger Baxter; Edward A Belongia; Matthew F Daley; Steven J Jacobsen; Allison Naleway; James D Nordin; Grace M Lee Journal: Pharmacoepidemiol Drug Saf Date: 2014-02-04 Impact factor: 2.890
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Sonja J Olsen; Joseph S Bresee; Karen R Broder; Ruth A Karron Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-07 Impact factor: 17.586